India Pharma - Pick-Up In Acute Therapies Supporting IPM Growth In July: Motilal Oswal

Motilal Oswal Report

The India pharma market grew 11.2% YoY in July 2024 (versus 6.9% in June-24 and 6.8% in July 2023). The growth in July 2024 was driven by strong seasonality. The acute therapies registered 11% YoY growth in July-24 versus 5% growth in July 2023.

Expect respiratory/gynaec, all other therapies registered double-digit growth during July-24. Interestingly, Ophthal recorded a decline of 7.7% YoY in July-24.

For the 12-month ending in July-24, IPM grew 8% YoY. This growth was led by price/new launches, which contributed +4.3% YoY/2.7% YoY to the overall growth over the same period.

Of the top 10 brands, LIV-52 /ZERODOL-SP/PAN-D registered a high double-digit growth of 28%/26%/24% YoY to Rs 610 million/Rs 540 million/Rs 550 million in July-24.

Of the top 40 brands, Mixtard/Dexorange posted a decline of 5%/2% YoY in July-24.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.